597511 Disclosed herein are diazohomoadamantane derivatives of formula (I), wherein X is CH2 or C=O and R is defined in the specification, and the use thereof in the treatment or prevention of conditions, disorders or deficits modulated by an alpha7 nicotinic acetylcholine receptor, an alpha4beta2 nicotinic acetylcholine receptor or both alpha7 and alpha4beta2 nicotinic acetylcholine receptor wherein the condition, disorder or deficit is selected from the group consisting of a memory disorder, cognitive disorder, neurodegeneration, and neurodevelopmental disorder. Exemplary compounds include: 4-(thieno[2,3-c]pyridin-5-ylcarbonyl)-1,4-diazatricyclo[4.3.1.13,8]undecane； 4-(5-phenyl-1,3,4-oxadiazol-2-yl)-1,4-diazatricyclo[4.3.1.13,8]undecane； N-[3-(1,4-diazatricyclo[4.3.1.13,8]undec-4-ylcarbonyl)phenyl]acetamide； and 4-[5-(4-fluorophenyl)-1,3-thiazol-2-yl]-1,4-diazatricyclo[4.3.1.13,8]undecane.
